Skip to content
Search

Latest Stories

RPS: Pharmacy staff should follow Covid-19 infection control procedures

The Royal Pharmaceutical Society (RPS) has recommended that pharmacists and pharmacy staff should follow Covid-19 infection control procedures including self isolation.

Last month, the Pharmacists’ Defence Association (PDA) had raised its concern over Well Pharmacy's policy of allowing Covid-19 positive staff to work in pharmacies, risking the health of colleagues and patients.


RPS said: “Pharmacies are health care environments which are accessed by patients who may be vulnerable to Covid infection. It is essential that mitigations are observed to prevent the spread of Covid by both the public and by pharmacy staff in all health care environments, including community pharmacies and other patient-facing pharmacy services such as in general practices and hospitals.

“Pharmacists and pharmacy staff have a professional responsibility to follow infection control procedures to protect patients. This includes self-isolating if they have tested positive for Covid-19, or have symptoms of a respiratory infection and high temperature. Equally, the public should continue to wear face coverings in pharmacies.”

After being brought to PDA’s attention by its member on symptomatic employees being allowed to attend a branch, the association sought a clarification from Well Pharmacy on allowing Covid positive staff to work in pharmacies.

The PDA said: “The pharmacy superintendent has since confirmed that is in line with company policy which states, “isolation is a personal choice” and confirms that such an approach “is in line with the Government Living with Covid guidance”.

The association reminded Responsible Pharmacists (RP) that they play an essential role in deciding what is safe for patients and colleagues in the pharmacy, when faced with staff members at work who have tested positive for Covid-19.

“Regrettably the policy of at least one major pharmacy multiple means that Covid-19 positive staff are permitted to attend work, which has the potential to expose vulnerable patients and staff to risk of infection,” said PDA.

The PDA share the concerns of members that vulnerable patients and vulnerable colleagues who have a reasonable expectation of rigorous infection control procedures in any healthcare setting, could be exposed to the Covid-19 virus by the policy of permitting positive Covid-19 employees to attend work.

“The policy of this pharmacy multiple appears at odds with the latest NHS Guidance on Managing healthcare staff with symptoms of a respiratory infection or a positive COVID-19 test result which states: All healthcare staff who have received a positive COVID-19 test result, regardless of whether they have symptoms, are advised not to attend work for 5 days. They should follow guidance for people with a positive COVID-19 test result Patient-facing healthcare staff can return to work when they have had 2 consecutive negative LFD test results (taken at least 24 hours apart).”

The association also assured that pharmacists who raise legitimate concerns about infection risks to their employer as set out above will be protected by whistleblowing legislation. The whistleblowing provisions protect any ‘worker’ who makes a ‘protected disclosure’ of information, from being dismissed or penalised by their employer because of the disclosure.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less